The issue of poor data integrity in India, which surfaced nine years ago at several Ranbaxy facilities, now appears increasingly pervasive and intractable.
As FDA and European authorities get better at identifying and responding to this problem, they remain so far unable to strike at the root cause.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?